FDA Approves Pralsetinib for RET Fusion Positive Metastatic NSCLC
September 5th 2020The Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for the treatment of patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC), according to Genentech, the co-manufacturer of the drug.
On Clinicals and Coronavirus: COVID-19 Pandemic Shakes Up Nursing Education
August 30th 2020The coronavirus disease 2019 (COVID-19) pandemic has affected nursing school at both the graduate and undergraduate level. While online classes may be convenient, a lack of in-person and hands-on training is a clear downside for those learning the trade.
Cancer and Genetic Testing: Expert Answers Common Questions
August 2nd 2020Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types. While these personalized treatments are improving outcomes, navigating the landscape of genetic testing can leave patients with questions for their providers.